Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.

Nature communications - 17 Jun 2026

Panagioti Eleni, Kelley Hunter J, Ling Alexander L, Sejour Leinal, Saini Shikha, Goins William F, Roberts Daniel, Sotiriou Sotiris, Bryan Iorgulescu J, Dixon Karen O, Yaffe Michael B, Vlachos Ioannis S, Castro Maria G, Lawler Sean E, Freeman Gordon J, Kuchroo Vijay K, Antonio Chiocca E, Cook Charles H

Abstract excerpt

Oncolytic virotherapy represents a promising yet under-explored approach for precision cancer treatment, particularly when tailored to tumor-specific molecular profiles. Patients with high-grade isocitrate dehydrogenase (IDH) mutant astrocytomas have limited treatment options and poor prognoses. Here, we investigate the therapeutic efficacy of rQNestin34.5 v.2 (CAN-3110), an engineered oncolytic herpes simplex...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Herpesvirus 1, Human

Share to Isocitrate Dehydrogenase

Share to Nectins

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Virus Internalization

Source

Open in PubMed Open full text

Identifiers

PMID: 42310302
DOI: 10.1038/s41467-026-73974-5
PMCID: PMC13434784

Genes

IDH1
TIGIT
PVR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.PMID 42310302Read ↗

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma.Semantic proximity Read ↗

Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene TherapySemantic proximity Read ↗

DNA Demethylating Agents Synergize with Oncolytic HSV1 against Malignant GliomasSemantic proximity Read ↗

Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cellsSemantic proximity Read ↗

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.Semantic proximity Read ↗

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in GliomasSemantic proximity Read ↗

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsSemantic proximity Read ↗

Virus-Based Therapies for the Treatment of Recurrent High-Grade GliomaSemantic proximity Read ↗

Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1.Semantic proximity Read ↗

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.Semantic proximity Read ↗

Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity.Semantic proximity Read ↗

Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screeningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.